Assessment of Abuse Potential of Drugs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 18, 2017
February 3, 2025
6c9a2ccd-021a-4f93-a97e-5444b6de4fef
Related Documents
Botanical Drug Development: Guidance for Industry
Guidance DocumentDecember 29, 2016Center for Drug Evaluation and Research
Good ANDA Submission Practices Guidance for Industry
Guidance DocumentJanuary 26, 2022Center for Drug Evaluation and Research
Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals
Guidance DocumentJune 5, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.